M
Marcelo Capra
Researcher at Universidade Federal do Rio Grande do Sul
Publications - 22
Citations - 452
Marcelo Capra is an academic researcher from Universidade Federal do Rio Grande do Sul. The author has contributed to research in topics: Population & Therapeutic drug monitoring. The author has an hindex of 11, co-authored 22 publications receiving 226 citations.
Papers
More filters
Journal ArticleDOI
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
Philippe Moreau,Meletios-Athanasios Dimopoulos,Joseph Mikhael,Kwee Yong,Marcelo Capra,Thierry Facon,Roman Hájek,Ivan Spicka,Ross I. Baker,Kihyun Kim,Gracia Martinez,Chang-Ki Min,Ludek Pour,Xavier Leleu,Albert Oriol,Youngil Koh,Kenshi Suzuki,Marie-Laure Risse,Gaëlle Asset,Sandrine Macé,Thomas Martin +20 more
TL;DR: In this article, the authors compared the efficacy of isatuximab plus carfilzomib-dexamethasone versus CARF-DEXAMETHASONE in patients with relapsed or refractory multiple myeloma.
Journal ArticleDOI
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial
Matthew J. Matasar,Marcelo Capra,Muhit Ozcan,Fangfang Lv,Wei Li,Eduardo Yanez,Katya Sapunarova,T. Lin,Jie Jin,Wojciech Jurczak,Aryan Hamed,Ming-Chung Wang,Ross Baker,Igor Bondarenko,Qingyuan Zhang,Jifeng Feng,Klaus Geissler,Mihaela Lazaroiu,Güray Saydam,Árpád Szomor,Krimo Bouabdallah,Rinat Galiulin,Toshiki Uchida,Lidia Mongay Soler,Anjun Cao,Florian Hiemeyer,Aruna Mehra,Barrett H. Childs,Yuankai Shi,Pier Luigi Zinzani +29 more
TL;DR: In this article, copanlisib was combined with rituximab to improve progression-free survival in patients with relapsed indolent non-Hodgkin lymphoma.
Journal ArticleDOI
Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma
Meletios A. Dimopoulos,Sara Bringhen,Pekka Anttila,Marcelo Capra,Michele Cavo,Craig E. Cole,Cristina Gasparetto,Vania Hungria,Matthew W Jenner,Vladimir I. Vorobyev,Eduardo Yanez Ruiz,Jian Y Yin,Rao Saleem,Maeva Hellet,Sandrine Macé,Bruno Paiva,Ravi Vij +16 more
TL;DR: Adding dexamethasone to isatuximab increased response rates and survival outcomes with no detrimental effect on safety in relapsed/refractory multiple myeloma.
Journal ArticleDOI
DBS sampling in imatinib therapeutic drug monitoring: from method development to clinical application.
Marina Venzon Antunes,Suziane Raymundo,Sandrine Comparsi Wagner,Sandrine Comparsi Wagner,Vanessa Suñé Mattevi,Natalia Vieira,Renata Leite,Fabiola Reginato,Marcelo Capra,Laura Fogliatto,Rafael Linden +10 more
TL;DR: IM can be measured in DBS using UHPLC-MS/MS with results comparable to those obtained in blood plasma, and is stable at DBS maintained at 40°C for 36 days.
Journal ArticleDOI
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
Katja Weisel,Andrew Spencer,Suzanne Lentzsch,Hervé Avet-Loiseau,Tomer M Mark,Ivan Spicka,Tamás Masszi,Birgitta Lauri,Mark-David Levin,Alberto Bosi,Vania Hungria,Michele Cavo,Je-Jung Lee,Ajay K. Nooka,Hang Quach,Markus Munder,Cindy Lee,Wolney Barreto,Paolo Corradini,Chang-Ki Min,Asher Chanan-Khan,Noemi Horvath,Marcelo Capra,Meral Beksac,Roberto Ovilla,Jae Cheol Jo,Ho Jin Shin,Pieter Sonneveld,Tineke Casneuf,Nikki A. Deangelis,Himal Amin,Jon Ukropec,Rachel Kobos,Maria-Victoria Mateos +33 more
TL;DR: New data reinforce the effectiveness and tolerability of daratumumab-based regimens for RRMM, regardless of cytogenetic risk status, as well as the safety profile of CASTOR.